-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, F5sYJDwt/ZKKSRk05QIZpC99enu9lound0vFPoGPo3MPvRfGfM6WYsRp0mKM1rGz 9cGboILiQamXs9b4tAwOvA== 0000812796-05-000010.txt : 20060413 0000812796-05-000010.hdr.sgml : 20060413 20050405135510 ACCESSION NUMBER: 0000812796-05-000010 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20050405 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DOR BIOPHARMA INC CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1691 MICHIGAN AVE. STREET 2: SUITE 435 CITY: MIAMI STATE: FL ZIP: 33139 BUSINESS PHONE: 305-534-3383 MAIL ADDRESS: STREET 1: 1691 MICHIGAN AVE. STREET 2: SUITE 435 CITY: MIAMI STATE: FL ZIP: 33139 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm DOR ACCELERATION REQUEST FOR S-3 FEB 2005

DOR BIO PHARMA, INC.
 
 
April 5, 2005
 
BY FACSIMILE AND EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler

Re: DOR BioPharma, Inc.
Registration Statement on Form S-3
File No. 333-123281

 
Ladies and Gentlemen:
 
 
The undersigned hereby respectfully requests, pursuant to Rule 461 of the Securities Act of 1933, as amended, that the Registration Statement on Form S-3 originally filed with the Securities and Exchange Commission (the “Commission”) on March 11, 2005 (File No. 333-123281) by DOR BioPharma, Inc. (the “Company”) be declared effective as of 5:00 p.m. (EST), or as soon as possible thereafter, on Wednesday, April 6, 2005.
 
The undersigned hereby acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and (iii) the Company may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
 
Very truly yours,
 
 
DOR BIOPHARMA, INC.


By:/s/ Michael T.Sember
Michael T. Sember
President and Chief Executive Officer

cc: Leslie J. Croland, Esq.

 -----END PRIVACY-ENHANCED MESSAGE-----